Evidence map›Paper›PMID 26669280›Full record

Trial reportScientific reports2015

Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer.

Erina Takai, Yasushi Totoki, Hiromi Nakamura, Chigusa Morizane, Satoshi Nara, Natsuko Hama, Masami Suzuki, Eisaku Furukawa, Mamoru Kato, Hideyuki Hayashi and 7 more

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05400681 (Pre- and Postoperative Incidence and Prognostic Implication of Positive Peritoneal Lavage and Circulating Tumor DNA in Patients With Pancreatic Cancer), which is not on this map. Cited by 106 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05400681 unknown statusnot on this mapstarted 2020, after this paper: background citation

Pre- and Postoperative Incidence and Prognostic Implication of Positive Peritoneal Lavage and Circulating Tumor DNA in Patients With Pancreatic Cancer

Typeobservational_patient_registrySponsorSonke DetlefsenRan2020 to 2024Enrolled200ConditionsPancreatic Cancer, Pancreatic Adenocarcinoma
3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Ultra-sensitive detection of mutantFrontiers in oncology · 2025
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Erina TakaiDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Yasushi TotokiDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Hiromi NakamuraDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Chigusa MorizaneDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo 1040045, Japan.
Satoshi NaraHepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, Tokyo 1040045, Japan.
Natsuko HamaDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Masami SuzukiDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Eisaku FurukawaDepartment of Bioinformatics, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Mamoru KatoDepartment of Bioinformatics, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Hideyuki HayashiDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo 1040045, Japan.
Takashi KohnoDivision of Genome Biology, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Hideki UenoDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo 1040045, Japan.
Kazuaki ShimadaHepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, Tokyo 1040045, Japan.
Takuji OkusakaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo 1040045, Japan.
Hitoshi NakagamaDivision of Carcinogenesis and Cancer Prevention, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Tatsuhiro ShibataDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Shinichi YachidaDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo 1040045, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. The genomic landscape of the PDAC genome features four frequently mutated genes (KRAS, CDKN2A, TP53, and SMAD4) and dozens of candidate driver genes altered at low frequency, including potential clinical targets. Circulating cell-free DNA (cfDNA) is a promising resource to detect and monitor molecular characteristics of tumors. In the present study, we determined the mutational status of KRAS in plasma cfDNA using multiplex picoliter-droplet digital PCR in 259 patients with PDAC. We constructed a novel modified SureSelect-KAPA-Illumina platform and an original panel of 60 genes. We then performed targeted deep sequencing of cfDNA and matched germline DNA samples in 48 patients who had ≥1% mutant allele frequencies of KRAS in plasma cfDNA. Importantly, potentially targetable somatic mutations were identified in 14 of 48 patients (29.2%) examined by targeted deep sequencing of cfDNA. We also analyzed somatic copy number alterations based on the targeted sequencing data using our in-house algorithm, and potentially targetable amplifications were detected. Assessment of mutations and copy number alterations in plasma cfDNA may provide a prognostic and diagnostic tool to assist decisions regarding optimal therapeutic strategies for PDAC patients.

Indexed as

Carcinoma, Pancreatic DuctalDNA, NeoplasmMutationPancreatic NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedProto-Oncogene Proteins p21(ras)DNA, NeoplasmKRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID26669280
PMCPMC4680882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.